Group 1 - The core point of the article is that China Hong Kong Energy (00931) has seen its stock price increase by over 5%, currently trading at 0.6 HKD with a trading volume of 6.4045 million HKD [1] - The company has stated that it is unaware of any reasons for the fluctuations in stock price and trading volume, and its business operations remain normal [1] - As of October, the company has been negotiating the acquisition of a large-scale liquefied natural gas project since May 1, and has signed confidentiality agreements with a liquefied natural gas user company on September 12 and with an international financial company on July 1 and August 1 for project financing support [1] Group 2 - The board of the company is considering expanding its capital base by inviting the aforementioned international financial company to subscribe for company shares at a discount to the market price, aiming to improve the company's financial performance and condition [1] - As of the date of the announcement, discussions regarding the share placement are still ongoing, and no agreements have been reached regarding the terms and details [1]

Core Viewpoint - China Port Energy (00931) has experienced a stock price increase of over 5% during trading, with a current price of 0.59 HKD and a trading volume of 6.4483 million HKD. The company has stated that it is unaware of any reasons for the fluctuations in stock price and trading volume, and its business operations remain normal [5]. Group 1 - The company is in discussions to acquire a large-scale liquefied natural gas (LNG) project since May 1 [5]. - On September 12, the company signed a confidentiality agreement with an LNG user company, and on July 1 and August 1, it signed confidentiality agreements and a memorandum of understanding with an international financial company for project financing support [5]. - The board is considering expanding the company's capital base by inviting the aforementioned international financial company to subscribe for shares at a discount to the market price, aiming to improve the company's financial performance and condition [5].

Core Viewpoint - China Port Energy (00931) has experienced a stock price increase of over 5%, currently trading at 0.6 HKD with a transaction volume of 6.4045 million HKD, despite the company stating it is unaware of any reasons for the stock price and trading volume fluctuations [1] Group 1 - The company has been in discussions since May 1 regarding the acquisition of a large-scale liquefied natural gas project [1] - On September 12, the company signed a confidentiality agreement with a liquefied natural gas user company, and on July 1 and August 1, it signed confidentiality agreements and a memorandum of understanding with an international financial company for project financing support [1] - The board is considering expanding the company's capital base by inviting the aforementioned international financial company to subscribe for shares at a discount to the market price, aiming to improve the company's financial performance and condition [1] Group 2 - As of the date of the announcement, discussions regarding the share placement are ongoing, and no agreements have been reached regarding the terms and details [1]

雅高控股(03313)发布公告，于2025年12月5日，配售代理与公司订立配售协议，据此，公司已有条件地 同意由配售代理尽最大努力向不少于六名承配人配售最多2.37亿股配售股份，配售价为每股配售股份 0.106港元，而该等承配人及其最终实益拥有人为独立第三方。配售股份将根据一般授权配发及发行。 假设于本公告日期至完成日期期间，公司已发行股本并无任何变更，则配售事项下的配售股份上限数目 2.37亿股相当于本公告日期公司现有已发行股本11.85亿股股份约20.00%;及经配发及发行配售股份扩大 的公司已发行股本约16.67%。配售事项项下的配售股份上限数目的总面值将为237万港元。 预期配售事项的所得款项总额及所得款项净额(于扣除配售佣金及其他相关开支后)上限将分别为约2512 万港元及约2477万港元。每股配售股份的净价约为0.1045港元。 配售价每股配售股份0.106港元较股份于配售协议日期在联交所所报收市价每股股份0.132港元折让约 19.70%。 ...

Core Viewpoint - The company, New Wave Pharmaceuticals (06108), has announced a placement agreement to issue up to 33.432 million shares at a price of HKD 0.225 per share, which represents a discount to the market price [1] Group 1: Placement Details - The maximum number of shares to be placed represents approximately 20.00% of the company's existing issued share capital as of the announcement date [1] - The placement price of HKD 0.225 per share reflects an 8.16% discount to the closing price of HKD 0.245 on the last trading day [1] - The placement price also shows a 10.57% discount compared to the average closing price of approximately HKD 0.2516 over the five trading days preceding the last trading day [1] Group 2: Financial Implications - The total gross proceeds from the placement are expected to be approximately HKD 7.5 million, with net proceeds estimated at around HKD 7.4 million after deducting placement fees and other expenses [1] - The net proceeds from the placement will be fully utilized for acquiring additional distribution rights related to the company's core business [1]

Core Viewpoint - The company, New Wave Pharmaceuticals (06108), has announced a placement agreement to issue up to 33.432 million shares at a price of HKD 0.225 per share, which represents a discount to the market price [1] Group 1: Placement Details - The placement will be made to at least six independent third-party investors [1] - The maximum number of shares to be placed represents approximately 20.00% of the company's existing issued share capital as of the announcement date, and about 16.66% of the enlarged issued share capital post-placement [1] - The placement price of HKD 0.225 per share reflects an 8.16% discount to the last closing price of HKD 0.245 and a 10.57% discount to the average closing price of HKD 0.2516 over the five trading days preceding the last trading day [1] Group 2: Financial Implications - The total gross proceeds from the placement are expected to be approximately HKD 7.5 million, with net proceeds estimated at around HKD 7.4 million after deducting placement fees and other expenses [1] - The net proceeds from the placement will be used entirely for acquiring additional distribution rights related to the company's core business [1]

配售股份最高数目为1亿股，相当于本公告日期公司全部已发行股本13.27亿股股份约7.54%，以及经配 售事项扩大的本公司全部已发行股本约7.01%。配售事项所得款项净额约为2941万港元(假设配售股份获 悉数配售，并于扣除所有相关开支后)将用作集团一般营运资金。 松景科技(01079)发布公告，于2025年12月4日，公司与配售代理订立配售协议，据此，配售代理已同意 代表公司按竭诚基准按每股配售股份0.30港元的价格配售最多1亿股新股份予独立承配人。 每股配售股份0.30港元。于2025年12月4日联交所报价的收市价每股股份0.330港元折让约9.09%. ...

格隆汇12月4日丨松景科技(01079.HK)公告，于2025年12月4日，公司与配售代理订立配售协议，据此， 配售代理已同意代表公司按竭诚基准按每股配售股份0.30港元的价格配售最多1亿股新股份予独立承配 人。配售事项须待(其中包括)联交所上市委员会批准或同意批准配售股份上市及买卖后，方可作实。倘 有关条件未获达成，则配售事项将不会进行。 每股配售股份0.30港元。配售价较于2025年12月4日(配售协议日期)联交所报价的收市价每股股份0.330 港元折让约9.09%；配售股份最高数目为1亿股，相当于本公告日期公司全部已发行股本1,326,701,739股 股份约7.54%，以及经配售事项扩大的公司全部已发行股本约7.01%。配售事项所得款项净额约为2941 万港元(假设配售股份获悉数配售，并于扣除所有相关开支后)将用作集团一般营运资金。 ...

Core Viewpoint - Xingkai Holdings (01166) has announced a placement agreement to issue up to 23.74 million shares at a price of HKD 0.37 per share, subject to approval from the listing committee [1][2] Group 1: Placement Details - The placement will involve a maximum of 23.74 million shares, representing approximately 20.00% of the company's existing issued share capital as of the announcement date [1] - The placement price of HKD 0.37 per share is at a premium of approximately 8.82% compared to the closing price of HKD 0.34 on December 3, 2025 [1] - The total nominal value of the maximum number of shares to be placed is HKD 4.748 million [1] Group 2: Financial Projections - If all placement shares are fully allocated, the expected total proceeds from the placement will be approximately HKD 8.7838 million [2] - The net proceeds from the placement, after deducting all applicable costs and expenses, including placement commissions and fees, are estimated to be around HKD 8.4838 million, resulting in a net price of approximately HKD 0.357 per share [2] - The company plans to use the net proceeds for approximately HKD 5 million for maintenance and repair expenses of investment properties, with the remainder allocated for general working capital [2]

Core Viewpoint - Xingkai Holdings (01166) has announced a placement agreement with a placement agent to issue up to 23.74 million shares at a price of HKD 0.37 per share, pending approval from the listing committee [1][2] Group 1: Placement Details - The placement involves a maximum of 23.74 million shares, representing approximately 20.00% of the company's existing issued share capital as of the announcement date [1] - The placement price of HKD 0.37 per share is at a premium of approximately 8.82% compared to the closing price of HKD 0.34 on December 3, 2025 [1] - If fully placed, the total expected gross proceeds from the placement will be approximately HKD 8.7838 million [2] Group 2: Use of Proceeds - The net proceeds from the placement, after deducting all applicable costs and expenses, including placement commissions and fees, are expected to be around HKD 8.4838 million [2] - Approximately HKD 5 million of the net proceeds will be allocated for maintenance and repair expenses of the group's investment properties, with the remainder used for general working capital [2]